SCOPUS 정보 검색 플랫폼

Volumn 10, Issue 3, 2010, Pages 203-210

Boceprevir

[No Author Info available]

Author keywords

Boceprevir; Hepatitis C; Research and development; therapeutic use; treatment

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN;

ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; HEPATITIS C; HUMAN; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MICROBIAL SENSITIVITY TESTS; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79952907374 PISSN: 11745886 EISSN: 11796901 Source Type: Journal
DOI: 10.2165/11586030-000000000-00000 Document Type: Article

Times cited : (4)

References (23)

1
- 79953178017
- Merck, 05 Nov, Media Release
- Merck. New Merck Begins Operations. www.merck.com, 05 Nov. 2009 Media Release
- (2009) New Merck Begins Operations

2
- 79953167291
- Merck and Co, 05 Aug, Media Release
- Merck and Co. In Pivotal Phase III Studies, Merck's Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response. www.merck.com, 05 Aug. 2010 Media Release
- (2010) Pivotal Phase III Studies, Merck's Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response

3
- 78649389302
- Schering-Plough Corporation, 20 Apr, Media Release
- Schering-Plough Corporation. Schering-Plough Reports Financial Results for First Quarter of 2006. www.scheringplough.com, 20 Apr. 2006 Media Release
- (2006) Schering-plough Reports Financial Results for First Quarter of 2006

4
- 79953201668
- Schering-Plough Inc, 02 Nov, Media Release
- Schering-Plough Inc. Results from two Cńdian studies confirm sustained viral response rates seen in hepatitis C patients treated with PEGETRON (R). www.scheringplough.com, 02 Nov. 2009 Media Release
- (2009) Results From Two Cńdian Studies Confirm Sustained Viral Response Rates Seen in Hepatitis C Patients Treated with PEGETRON (R)

5
- 79953165492
- Schering-Plough Corporation, 27 Jan, Media Release
- Schering-Plough Corporation. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients. www.schering-plough.com, 27 Jan 2009 Media Release
- (2009) Schering-plough Completes Enrollment of Boceprevir Registration Studies in Treatment-naive and Treatment-experienced HCV Patients

6
- 79953165857
- Schering-Plough Corporation, 24 Nov, Media Release
- Schering-Plough Corporation. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C. www.schering-plough.com, 24 Nov. 2008 Media Release
- (2008) Schering-plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-generation Oral. HCV Protease Inhibitor for Treating Patients with Chronic Hepatitis C

7
- 79953220618
- Schering-Plough Corporation, 23 Apr, Media Release
- Schering-Plough Corporation. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients. www.schering-plough. com, 23 Apr. 2009 Media Release
- (2009) Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-naive Genotype 1 Hepatitis C Patients

8
- 79953206044
- Schering-Plough Corporation, 04 Aug, Media Release
- Schering-Plough Corporation. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients. www.schering-plough.com, 04 Aug. 2008 Media Release
- (2008) Top-line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-naive Hepatitis C Patients

9
- 62949217755
- Schering-Plough Corporation, 18 Oct, Media Release
- Schering-Plough Corporation. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response (Part A). www.schering-plough.com, 18 Oct. 2007 Media Release
- (2007) Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-naive Hepatitis C Patients Show A High Rate of Early Virologic Response (Part A)

10
- 79953205707
- Schering-Plough Corporation, 20 Apr, Media Release
- Schering-Plough Corporation. Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH 503034 Clinical Development Program for Hepatitis C. www.schering-plough.com, 20 Apr. 2006 Media Release
- (2006) Schering-plough Provides Update on Oral. HCV Protease Inhibitor SCH 503034 Clinical Development Program for Hepatitis C

11
- 42349087382
- Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation
- No. 4, Oct, USA English
- Zhang J, Gupta S, Rouzier R, et al. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation. Hepatology. 42 (Suppl. 1):535, No. 4, Oct. 2005. USA [English]
- (2005) Hepatology , vol.42 , Issue.1 SUPPL. , pp. 535
- Zhang, J.¹ Gupta, S.² Rouzier, R.³

12
- 30344485556
- Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon
- plus oral presentation abstr. 94, No. 4, Oct, Germany English. Clinical Trials Insight
- Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon. Hepatology. 42 (Suppl. 1):233-234 (plus oral presentation) abstr. 94, No. 4, Oct. 2005. Germany [English]. Clinical Trials Insight
- (2005) Hepatology , vol.42 , Issue.1 SUPPL. , pp. 233-234
- Zeuzem, S.¹ Sarrazin, C.² Rouzier, R.³

13
- 79953189528
- Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral biov́ilability: Potential therapeutic agent for treating hepatitis C viral infection
- MEDI abstr. 252 plus oral, 28 Aug, England English
- Njoroge FG, Arśppan A, Bennett F, et al. Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral biov́ilability: potential therapeutic agent for treating hepatitis C viral infection. 230th National Meeting of the American Chemical Society. (CD-ROM): MEDI abstr. 252 (plus oral), 28 Aug. 2005. England [English]
- (2005) 230th National Meeting of the American Chemical Society. (CD-ROM)
- Njoroge, F.G.¹ Arśppan, A.² Bennett, F.³

14
- 79953227834
- Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus pegintron TM (peginterferon alfa-2B)/ribavirin in treatment-naive subjects with genotype-1 CHC
- Late Breaking Abstr.: 23 Apr, Available from URL:, USA English. Clinical Trials Insight
- Kwo P, Lawitz E, McCone J, et al. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus pegintron TM (peginterferon alfa-2B)/ribavirin in treatment-naive subjects with genotype-1 CHC. 43rd Annual Meeting of the European Association for the Study of the Liver. (Late Breaking Abstr.): 23 Apr. 2008. Available from URL: http://www.easl.ch/liver-meeting. USA [English]. Clinical Trials Insight
- (2008) 43rd Annual Meeting of the European Association for the Study of the Liver
- Kwo, P.¹ Lawitz, E.² McCone, J.³

15
- 79953170700
- Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin in patients with chronic hepatitis C, genotype 1
- 14 Apr, Available from URL:, USA English
- Vierling JM, Ralston R, Lawitz EJ, et al. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin in patients with chronic hepatitis C, genotype 1. 45th Annual Meeting of the European Association for the Study of the Liver: 14 Apr. 2010. Available from URL: http://www.easl.ch/easl2010. USA [English]
- (2010) 45th Annual Meeting of the European Association for the Study of the Liver
- Vierling, J.M.¹ Ralston, R.² Lawitz, E.J.³

16
- 79953209844
- Clonal ńlysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders sequentially treated with boceprevir (SCH503034) and/or pegylated interferon alfa-2b (PEG-IFN alfa-2B)
- abstr. 1592, 30 Oct, Available from URL:, Germany English. Clinical Trials Insight
- Vermehren J, Susser S, Karey U, et al. Clonal ńlysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders sequentially treated with boceprevir (SCH503034) and/or pegylated interferon alfa-2b (PEG-IFN alfa-2B). 60th Annual Meeting of the American Association for the Study of Liver Diseases: abstr. 1592, 30 Oct. 2009. Available from URL: http://www.aasld.org/the livermeeting/Pages/default.aspx. Germany [English]. Clinical Trials Insight
- (2009) 60th Annual Meeting of the American Association for the Study of Liver Diseases
- Vermehren, J.¹ Susser, S.² Karey, U.³

17
- 77950211035
- Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevir
- plus oral presentation, 22 Apr, Available from URL:, Germany English
- Susser S, Forestier N, Welker MW, et al. Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevir. 44th Annual Meeting of the European Association for the Study of the Liver: (plus oral presentation), 22 Apr. 2009. Available from URL: http://www2.kenes.com. Germany [English]
- (2009) 44th Annual Meeting of the European Association for the Study of the Liver
- Susser, S.¹ Forestier, N.² Welker, M.W.³

18
- 33644758023
- Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders: Phase IB results
- plus oral presentation abstr. 201, No. 4, Oct, Germany English. Clinical Trials Insight
- Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders: phase IB results. Hepatology. 42 (Suppl. 1):276-277 (plus oral presentation) abstr. 201, No. 4, Oct. 2005. Germany [English]. Clinical Trials Insight
- (2005) Hepatology , vol.42 , Issue.1 SUPPL. , pp. 276-277
- Zeuzem, S.¹ Sarrazin, C.² Wagner, F.³

19
- 53149114987
- HCV polymerase (NM107) and protease (boceprevir) inhibitors in combination show enhanced activity and suppression of resistance in the replicon system
- No. 4, Oct, USA English
- Standring DN, Bichko V, Chase R, et al. HCV polymerase (NM107) and protease (boceprevir) inhibitors in combination show enhanced activity and suppression of resistance in the replicon system. Hepatology. 46 (Suppl. 1):857, No. 4, Oct. 2007. USA [English]
- (2007) Hepatology , vol.46 , Issue.1 SUPPL. , pp. 857
- Standring, D.N.¹ Bichko, V.² Chase, R.³

20
- 33646843732
- SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease suppresses polyprotein maturation and enhances the antiviral activity of interferon-A-2B
- No. 4, Oct, USA English
- Malcolm BA, Arassappan A, Bennett F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease suppresses polyprotein maturation and enhances the antiviral activity of interferon-A-2B. Hepatology. 42 (Suppl. 1):535-536, No. 4, Oct. 2005. USA [English]
- (2005) Hepatology , vol.42 , Issue.1 SUPPL. , pp. 535-536
- Malcolm, B.A.¹ Arassappan, A.² Bennett, F.³

21
- 79953230253
- Schering-Plough Corporation, 01 Nov, Media Release
- Schering-Plough Corporation. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28-and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients. www.schering-plough.com, 01 Nov. 2008 Media Release
- (2008) Boceprevir Phase II Study Showed High Rate of Sustained Response with 28-and 48-week Regimens in Genotype 1 Treatment-naive Hepatitis C Patients

22
- 79953185868
- Schering-Plough Corporation, 26 Apr, Media Release
- Schering-Plough Corporation. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL. www.scheringplough.com, 26 Apr. 2008 Media Release
- (2008) Interim Results From Boceprevir Phase II Study in Genotype 1 Treatment-naive Hepatitis C Patients Presented at EASL

23
- 79953201304
- Schering-Plough Corporation, 01 Nov, Media Release
- Schering-Plough Corporation. Dt́ Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting. www.schering-plough.com, 01 Nov. 2009 Media Release
- (2009) Dt́ Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.